Skip to main content

Prevention

1
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
EsomeprazolePhase 3Small Molecule1 trial
Active Trials
NCT01069939Completed427Est. Nov 2011
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
PrEP N' Shine: Strength Based Case ManagementN/A1 trial
Stage 1 Strength Based Case ManagementN/A1 trial
Active Trials
NCT05016232Completed123Est. Jun 2024
NCT05736614Recruiting500Est. Jun 2026
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Intervention GroupN/A1 trial
Active Trials
NCT04977700Completed41Est. Jun 2023
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
1 program
edoxabanPHASE_31 trial
Active Trials
NCT01181167Completed610Est. Mar 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaEsomeprazole
Daiichi Sankyoedoxaban
Angeles TherapeuticsStage 1 Strength Based Case Management
Angeles TherapeuticsPrEP N' Shine: Strength Based Case Management
Colorado TherapeuticsIntervention Group

Clinical Trials (5)

Total enrollment: 1,701 patients across 5 trials

NCT01069939AstraZenecaEsomeprazole

Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin

Start: Feb 2010Est. completion: Nov 2011427 patients
Phase 3Completed
NCT01181167Daiichi Sankyoedoxaban

A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

Start: May 2009Est. completion: Mar 2010610 patients
Phase 3Completed
NCT05736614Angeles TherapeuticsStage 1 Strength Based Case Management

Optimizing PrEP Uptake and Adherence Among Male Sex Workers

Start: Nov 2022Est. completion: Jun 2026500 patients
N/ARecruiting
NCT05016232Angeles TherapeuticsPrEP N' Shine: Strength Based Case Management

Adaptive Intervention to Facilitate PrEP Uptake/Adherence Among Transgender Women

Start: Oct 2022Est. completion: Jun 2024123 patients
N/ACompleted
NCT04977700Colorado TherapeuticsIntervention Group

Using Physical Tracking to Predict Sunburn

Start: Sep 2020Est. completion: Jun 202341 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,701 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.